Visão geral da empresa
A clinical-stage biotechnology entity, Upstream Bio, Inc. focuses on developing therapeutic interventions specifically targeted at inflammatory diseases, with a primary emphasis on severe respiratory disorders such as asthma and chronic obstructive pulmonary conditions. Operating within the Healthcare sector and the Biotechnology industry, the company functions in a high-risk, high-reward environment where capital is primarily directed toward advancing research and development to bring novel treatments to market. The organization employs a workforce of 75 individuals and holds a market capitalization of $535.49M, reflecting a valuation significantly higher than its current annual revenue of $2.85M. This disparity between market cap and revenue indicates that the market is pricing the company based on the potential future value of its drug candidates and pipeline assets rather than current profitability, a common characteristic of early-stage biotech firms where investor sentiment is driven by clinical trial milestones and regulatory approval prospects rather than cash flow generation.
Saúde financeira
The company reported annual revenue of $2.85M over the trailing twelve months, accompanied by a net income of $-143,443,008 and an EBITDA of $-160,172,992, revealing a substantial gap between top-line generation and bottom-line profitability that underscores the heavy investment required in R&D and operational scaling. Free cash flow stands at $-88,750,624, which signifies that the company is currently consuming cash to fuel its growth initiatives and clinical programs rather than generating surplus liquidity for distribution or debt repayment. The gross margin is recorded at 100.0%, suggesting that cost of goods sold is negligible or zero for the company's current product portfolio, while the operating margin of -6911.2% and profit margin of 0.0% highlight severe inefficiencies or high fixed cost structures typical of pre-commercialization stages where operating expenses vastly exceed revenue. The balance sheet displays $341.51M in cash against only $1.27M in debt, creating a highly conservative position where liquidity assets dwarf liabilities, and the debt-to-equity ratio of 0.37 further confirms minimal leverage relative to shareholder equity. With a current ratio of 26.15, the company possesses immense short-term liquidity, indicating an ability to meet its obligations with over 26 times the current assets available, effectively eliminating default risk in the near term. Return on Equity is negative at -35.4% and Return on Assets is -24.0%, metrics that reveal that management is currently generating losses on the capital deployed, a standard outcome for development-stage companies that have not yet achieved commercial product sales.
Avaliação de valorização
The valuation metrics present a complex picture, with a trailing P/E ratio listed as N/A due to the lack of positive earnings, while the forward P/E is recorded at -3.05, implying that future earnings estimates are projected to remain negative or are being calculated on a basis that does not yet reflect profitability. The price-to-book ratio stands at 1.57, indicating that the market values the company at a 57% premium over its net asset book value, a multiple often justified by the intangible value of intellectual property and clinical data that are not captured on the balance sheet. Alternative valuation multiples show a price-to-sales ratio of 187.63 and an EV/EBITDA of -1.22, suggesting that investors are willing to pay a significant multiple for every dollar of sales despite the lack of earnings, driven by the potential upside of the pipeline. The stock has exhibited significant volatility within the past year, trading between a 52-week low of $5.14 and a 52-week high of $33.68, meaning the current market price sits at a level that reflects substantial movement from the absolute lows but remains below the recent peak. Although the beta value is listed as N/A, the wide range between the high and low prices suggests that the stock's price volatility is considerable relative to the broader market, making it sensitive to specific biotech sector sentiment and clinical trial outcomes.
Growth & Income
Revenue growth for the year-over-year period is 9.0%, while earnings growth is N/A, indicating that the company is expanding its top line but has not yet reached a stage where positive earnings growth can be measured or calculated. Since the company is not a dividend payer, the dividend yield and payout ratio are both N/A, meaning the firm retains all its cash flow to reinvest into research and development rather than distributing income to shareholders. The absence of a dividend payout ratio confirms that the company reinvests its earnings—or in this case, its cash reserves—directly into advancing its clinical-stage treatments and expanding its operational capabilities to prepare for commercialization. The overall growth and income profile for Upstream Bio, Inc. is characterized by moderate top-line expansion coupled with a complete absence of current profitability or income distribution, reflecting a strategic focus on long-term asset creation rather than immediate shareholder returns.